Raymond Q1 FY27 Concall: Strong Revenue Growth and Robust Order Pipeline
Raymond Limited reported Q1 FY27 total income of ₹628 crore, up 13% YoY, with EBITDA at ₹100 crore, up 14%. The Aerospace division revenue grew 40% to ₹123 crore, and Precision Technology revenue increased 11% to ₹444 crore. The company has a net cash surplus of ₹129 crore and a 10-year order book exceeding ₹5,960 crore.
The strong financial performance and positive outlook suggest a medium impact on investor sentiment and future growth prospects. The expansion plans and strategic initiatives also indicate a sustained growth trajectory.
The company reported strong year-on-year growth in revenue and EBITDA, driven by its key divisions. The robust order book and positive outlook on global trade conditions contribute to a positive sentiment.
Raymond Limited hosted its Q1 FY27 earnings conference call on August 7, 2026, with key management including Rakesh Tiwary (Group CFO) and Gautam Maini (MD, Engineering Business). The company reported a total income of ₹628 crore in Q1 FY27, a 13% increase year-on-year, with EBITDA growing by 14% to ₹100 crore, resulting in an EBITDA margin of 15.9%.
The performance was driven by the Aerospace, Defence, and Precision Technology divisions. The Aerospace and Defence business, under JK Maini Global Aerospace Limited, saw revenue grow by 40% to ₹123 crore and EBITDA by 25% to ₹26 crore, with an EBITDA margin of 21.2%. This segment benefits from a robust 10-year order book of over ₹5,960 crore and an active RFQ pipeline of ₹1,632 crore.
The Precision Technology and Auto Components segment, JK Maini Precision Technology Limited, reported revenue of ₹444 crore, an 11% year-on-year growth, with EBITDA at ₹61 crore, a 46% increase, and an EBITDA margin of 13.8%. A significant strategic initiative is the launch of an automotive aftermarket product line in Q2 FY27, capitalizing on OEM-grade manufacturing capabilities.
Raymond Limited maintains a net debt-free position with a net cash surplus of ₹129 crore as of June 2026. The company's INR 1,000 crore, 5-year capex plan is progressing on schedule, with the Andhra Pradesh greenfield facility targeted for commercial production in late 2027.
Management highlighted the favorable global trade environment, including the India-U.K. CETA agreement and the rollback of U.S. tariffs, which are boosting engineering exports. They also announced receiving certification for making medical components on the day of the call. The company is focused on moving up the value chain, increasing critical component and subassembly production, and expanding its customer base to reduce concentration.
What to do with a filing like this
Raymond Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Raymond Limited. Read the original for the full detail.